DALLAS–(BUSINESS WIRE)–AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, announced its participation in the National Association of Specialty Pharmacy (NASP) 2023 Annual Meeting and Expo, which took place on September 18th – 21st in Grapevine, Texas. At the NASP 2023 Annual Meeting and Expo, AIS Healthcare sponsored a continuing education symposium through an unrestricted educational grant that focused on the critical topic of USP 797 guideline revisions, a set of standards developed by U.S. Pharmacopeia (USP) governing the safe compounding of sterile preparations in healthcare settings, and its impact on the healthcare industry. These topics were discussed during panel discussions with industry experts and led by Katrina K. Harper, Director of Clinical Education, AIS Healthcare.
AIS Healthcare’s symposium, The 411 Before 911 on USP 797: Changes, Challenges, and Choices, featured speakers including:
- Anita Abata, PharmD, BCPD, BCCCP, BCSCP, Sterile Compounding Coordinator/Hazardous Drug Designated Person, John Peter Smith Inpatient Pharmacy/Oncology and Infusion Center
- Paul Menasco, PharmD, System Accreditation and Regulatory Compliance Pharmacist, Ochsner Health
- Ehigie Garvey Omorodion, PharmD, BCSCP, BCNSP, CNSC, CPPS, Pharmacy Manager IV Sterile Products/Oncology, Parkland Health & Hospital System
- Kirk Starr, MBA, PRh, System Director, Pharmacy Operations & Special Programs, Baylor Scott & White Health
- Cindy Dumas, RPh, PharmD, Vice President of Pharmacy Services, AIS Healthcare
AIS Healthcare is dedicated to advancing best practices across the specialty pharmacy industry. The NASP Annual Meeting and Expo served as a crucial platform for industry leaders to come together to promote the highest standards of sterility, quality, and safety in the development of compounded medications.
“Advancing quality and improving lives is at the center of what this event is about. The NASP 2023 Annual Meeting and Expo provided an important setting for experts within our industry to engage and learn from one another with the goal of best serving our patients’ unique needs. We were proud to facilitate important discussions about how we prioritize sterility, quality, and safety in all the medications we produce for patients,” said Simon Castellanos, CEO of AIS Healthcare.
USP 797 revisions become official and enforceable on November 1, 2023. Pharmacies preparing Category 3 compounded sterile preparations (CSPs), formerly known as high-risk preparations, now face more rigorous standards. These revisions will require increased staffing, training, and investment, all of which may pose challenges for pharmacies. AIS Healthcare is already meeting or exceeding these revised standards.
AIS Healthcare is honored to have participated in the NASP 2023 Annual Meeting and Expo and is committed to fostering innovation and excellence in pharmaceutical compounding. For more information about the NASP 2023 Annual Meeting and Expo, please visit www.naspmeeting.com.
About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
Contacts
Simon Castellanos
877.443.4006